THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 111 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,215,000 | -94.0% | 119,854 | -94.7% | 0.02% | -94.6% |
| Q2 2022 | $20,326,000 | +60.3% | 2,243,473 | +69.1% | 0.31% | +51.9% |
| Q1 2022 | $12,683,000 | +99.6% | 1,326,653 | +130.7% | 0.21% | +126.4% |
| Q4 2021 | $6,355,000 | -56.6% | 575,113 | -70.9% | 0.09% | -61.9% |
| Q3 2021 | $14,646,000 | +169.0% | 1,979,130 | +427.9% | 0.24% | +134.3% |
| Q2 2021 | $5,444,000 | – | 374,912 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |